Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors
Reversion of the malignant phenotype of erbB2-transformed cells can be driven by anti-erbB2/neu monoclonal antibodies (mAbs), which disrupt the receptor’s kinase activity. We examined the biologic effects of IFN-γ alone or after anti-erbB2/neu mAb treatment of erbB2-positive cells. IFN-γ had no effe...
Main Authors: | Yasuhiro Nagai, Hiromichi Tsuchiya, E. Aaron Runkle, Peter D. Young, Mei Q. Ji, Larry Norton, Jeffrey A. Drebin, Hongtao Zhang, Mark I. Greene |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-09-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124715009298 |
Similar Items
-
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors
by: Yasuhiro Nagai, et al.
Published: (2015-10-01) -
Ontogeny of the Neuregulin Receptor ErbB4 in the Rat Forebrain and Phenotypic Characterization of ErbB4-Deficienct Mice
by: Hau-Jie Yau, et al.
Published: (2006) -
Analysis of ErbB Receptors: Regulation of ErbB-1 Kinase Activation and Localization of ErbB-4 to Membrane Microdomains
by: Thiel, Kristina Wyatt
Published: (2007) -
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
by: Guangyuan Li, et al.
Published: (2014-01-01) -
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
by: Diego Alvarado, et al.
Published: (2017-01-01)